SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Read more breaking news

 

 

An experienced CMO is key to successful biologics development says Cobra Biologics

By Gareth Macdonald , 25-Jan-2012
Last updated on 25-Jan-2012 at 15:16 GMT2012-01-25T15:16:15Z

An experienced CMO is key to successful biologics development says Cobra Biologics
An experienced CMO is key to successful biologics development says Cobra Biologics
Loading...

Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.

Outsourcing-pharma.com spoke with commercial director Julian Hanak who said that an experienced contract manufacturing organisation (CMO) - and detailed analysis of the market - can reduce the risks involved in developing biologics.

Drug development is a high attrition rate process. It’s very expensive to do, it’s highly regulated and it’s slow. What you don’t want is failures doing the basics, making the molecule, testing the molecule and shipping the molecule around.”

Asia

However – while experienced CMOs in the US and Europe still dominate – the growth of the Asian contracting sector is starting to alter market dynamics according to Hanak.

There are two sorts of companies [Asian CMOs]. There are companies… that are actually buying organisations in the western world and then there are those whose manufacturing assets are actually in the developing world,” he said, highlighting the BRIC nations as a particular.

There was a perception in the past that you couldn’t get quality from going outside developed western markets and I think that myth has been dispelled now. “

The challenges that Asian CMOs now face in attracting customers – and hence the advantage Western manufactures retain – are more related to distance, language and project oversight Hanak continued.

Nevertheless – there are still opportunities for experienced Western CMOs as regional markets begin to open up.

In terms of contract manufacturing, a lot of the technology and the expertise resides in Western and developed nations, so a lot of the more difficult to manufacture products at least start life and get launched from facilities in the Western world,” Hanak said, even if they are likely to be transferred elsewhere at the end of their lifecycles.

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

William Reed Business Media Holiday video

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Key Industry Events

 

Access all events listing

Our events, Events from partners...